Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

Summary

This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS patients receiving standard of care (SoC) therapy. Specifically, we will evaluate whether TET2-CHIP status predicts a differential response to colchicine. As a pilot study, it also aims to provide detailed data supporting design of further trial, such as sample size calculating, endpoint optimizing, etc.

Timeline

Start

2026-06-08

Primary completion

2027-12-01

Completion

2027-12-01

Drugs

Indications